Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 1, 2006, Pages 61-74

  Borges, Silvana ^a,b,c,d   Desta, Zeruesenay ^a,b,c,d   Li, Lang ^a,b,c,d   Skaar, Todd C ^a,b,c,d   Ward, Bryan A ^a,b,c,d   Nguyen, Anne ^a,b,c,d   Jin, Yan ^a,b,c,d   Storniolo, Anna Maria ^a,b,c,d   Nikoloff, D Michele ^a,b,c,d   Wu, Lin ^a,b,c,d   Hillman, Grant ^a,b,c,d   Hayes, Daniel F ^a,b,c,d   Stearns, Vered ^a,b,c,d   Flockhart, David A ^a,b,c,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Roche Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; CELECOXIB; CHLORPHENIRAMINE; CITALOPRAM; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; DIPHENHYDRAMINE; DRUG METABOLITE; ENDOXIFEN; FLUOXETINE; NORTAMOXIFEN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TAMOXIFEN; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; AGED; ALLELE; ANAMNESIS; ARTICLE; BREAST CANCER; CANCER THERAPY; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; METABOLITE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; TAMOXIFEN;

EID: 33745347897     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.03.013     Document Type: Article

References (35)

1. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer. report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
2. Osborne C.K. Tamoxifen in the treatment of breast cancer. N Engl J Med 339 (1998) 1609-1618
3. Desta Z., Ward B.A., Soukhova N.V., and Flockhart D.A. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro. prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310 (2004) 1062-1075
4. Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance. focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 44 (2005) 349-366
5. Scripture C.D., Sparreboom A., and Figg W.D. Modulation of cytochrome P450 activity. implications for cancer therapy. Lancet Oncol 6 (2005) 780-789
6. Jordan V.C., Collins M.M., Rowsby L., and Prestwich G. A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity. J Endocrinol 75 (1977) 305-316
7. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95 (2003) 1758-1764
8. Clarke R., Liu M.C., Bouker K.B., Gu Z., Lee R.Y., Zhu Y., et al. Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22 (2003) 7316-7339
9. Lien E.A., Solheim E., Kvinnsland S., and Ueland P.M. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 48 (1988) 2304-2308
10. Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.H., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97 (2005) 30-39
11. Goetz M.P., Rae J.M., Suman V.J., Safgren S.L., Ames M.M., Visscher D.W., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 (2005) 9312-9318
12. Hou Z.Y., Pickle L.W., Meyer P.S., and Woosley R.L. Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther 49 (1991) 410-419
13. Dahl M.L., Johansson I., Palmertz M.P., Ingelman-Sundberg M., and Sjoqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51 (1992) 12-17
14. Sachse C., Brockmoller J., Bauer S., and Roots I. Cytochrome P450 2D6 variants in a Caucasian population. allele frequencies and phenotypic consequences. Am J Hum Genet 60 (1997) 284-295
15. Human Cytochrome P450 (CYP) Allele Nomenclature Committee Web site. Available from: URL:http://www.cypalleles.ki.se/cyp2d6.htm. Accessed Feb 15, 2006.
16. Zanger U.M., Raimundo S., and Eichelbaum M. Cytochrome P450 2D6. overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 23-37
17. Lundqvist E., Johansson I., and Ingelman-Sundberg M. Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226 (1999) 327-338
18. Dahl M.L., Johansson I., Bertilsson L., Ingelman-Sundberg M., and Sjoqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274 (1995) 516-520
19. Lonning P.E., Lien E.A., Lundgren S., and Kvinnsland S. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clin Pharmacokinet 22 (1992) 327-358
20. Adam H.K., Patterson J.S., and Kemp J.V. Studies on the metabolism and pharmacokinetics of tamoxifen in normal volunteers. Cancer Treat Rep 64 (1980) 761-764
21. Lee K.H., Ward B.A., Desta Z., Flockhart D.A., and Jones D.R. Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection. application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 791 (2003) 245-253
22. Desta Z., Kerbusch T., and Flockhart D.A. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 65 (1999) 10-20
23. Hersberger M., Marti-Jaun J., Rentsch K., and Hanseler E. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 46 Pt 1 (2000) 1072-1077
24. Raimundo S., Toscano C., Klein K., Fischer J., Griese E.U., Eichelbaum M., et al. A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 76 (2004) 128-138
25. Candiotti K.A., Birnbach D.J., Lubarsky D.A., Nhuch F., Kamat A., Koch W.H., et al. The impact of pharmacogenomics on postoperative nausea and vomiting. do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis?. Anesthesiology 102 (2005) 543-549
26. Schork N.J., Allison D.B., and Thiel B. Mixture distributions in human genetics research. Stat Methods Med Res 5 (1996) 155-178
27. McLachlan G., and Peel D. Finite mixture model (2000), John Wiley & Sons, New York 209-210
28. Balding D.J., Bishop M., and Cannings C. Handbook of statistical genetics (2001), John Wiley & Sons, New York 746-747
29. Schwarz G. Estimating the dimension of a model. Ann Stat 6 (1978) 461-464
30. Hemeryck A., and Belpaire F.M. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions. an update. Curr Drug Metab 3 (2002) 13-37
31. Barton D.L., Loprinzi C.L., Novotny P., Shanafelt T., Sloan J., Wahner-Roedler D., et al. Pilot evaluation of citalopram for the relief of hot flashes. J Support Oncol 1 (2003) 47-51
32. Plouffe Jr. L., Trott E.A., Largoza M., and Hansen K.A. An open trial of sertraline for menopausal hot flushes. potential involvement of serotonin in vasomotor instability. Del Med J 69 (1997) 481-482
33. Stearns V., Beebe K.L., Iyengar M., and Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes. a randomized controlled trial. JAMA 289 (2003) 2827-2834
34. Loprinzi C.L., Sloan J.A., Perez E.A., Quella S.K., Stella P.J., Mailliard J.A., et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20 (2002) 1578-1583
35. Loprinzi C.L., Kugler J.W., Sloan J.A., Mailliard J.A., LaVasseur B.I., Barton D.L., et al. Venlafaxine in management of hot flashes in survivors of breast cancer. a randomised controlled trial. Lancet 356 (2000) 2059-2063